Also known as: triple-negative disease
A drug-free wearable device that generates low-intensity electric fields reduced tumor growth and spread in preclinical models of triple-negative breast cancer. The treatment appeared to boost immune activity around tumors and will be tested in an upcoming NIH-sponsored clinical trial.
A study of 450 mTNBC patients in community practices found high biomarker testing rates and encouraging outcomes across racial groups, with Hispanic patients showing the longest survival. However, Black women of West African ancestry face the highest TNBC incidence and greater neuropathy from paclitaxel, making docetaxel a potential alternative. Social determinants like neighborhood deprivation and allostatic load are also linked to TNBC risk.
A JAMA Oncology study finds breast cancer patients using complementary and alternative medicine face a higher risk of death. A new molecule SU212 shows promise against triple-negative breast cancer, and global breast cancer cases are projected to rise to 3.5 million by 2050.
Lantern Pharma's LP-284 received FDA Orphan Drug Designation for soft tissue sarcomas, while the USPTO allowed a patent for biomarker-guided use of LP-184 in multiple cancers. LP-284 showed a complete metabolic response in a Phase 1 DLBCL patient, and LP-184 demonstrated a 45% disease control rate in advanced solid tumors.
A recent global analysis shows oncology dominates clinical trial activity in 2025, while Phase II attrition rates dropped to 26%—the lowest in four years. The US remains the leader in investigator sites, but China is the fastest-growing market. Obesity research is poised to break into the top five most-studied diseases.
BioNTech reported a Q1 2026 net loss of $622.3 million as revenue declined to $138.0 million and R&D spending rose to $651.6 million. The company expanded its oncology pipeline with five new pivotal trials for pumitamig and announced manufacturing site exits to save $584.9 million annually by 2029.
The FDA has cleared Telomir Pharmaceuticals' IND for Telomir-Zn in advanced or metastatic triple-negative breast cancer. The company plans to initiate a first-in-human Phase 1/2 trial in the first half of 2026.
A 64-year-old Australian man was diagnosed with stage 3 breast cancer after his wife noticed bloodstains on his shirt, a case doctors say highlights that men can and do get the disease. Meanwhile, advances in precision medicine now allow breast cancer treatment to be tailored to each tumour’s biology and the patient’s overall health.
The FDA approved six cancer therapies in Q2 2026, including first-line sacituzumab govitecan for triple-negative breast cancer and capivasertib for PTEN-deficient prostate cancer. A separate study shows 69% of accelerated-approval cancer drugs need safety updates within 4 years.
Intensity Therapeutics restarted its INVINCIBLE-4 Phase 2 trial of INT230-6 in presurgical triple-negative breast cancer, reporting 71.4% pCR with INT230-6 plus SOC versus 33% with SOC alone. 2025 cash stood at $11.9M with runway into Q2 2027.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07768436 |
A Study of Cyclophosphamide, Methotrexate, Fluorouracil (CMF) for People With Breast Cancer |
RECRUITING | PHASE2 |
| NCT07743632 |
Neoadjuvant Angiogenesis-Targeting Bispecific Chemoimmunotherapy for TNBC |
NOT_YET_RECRUITING | PHASE2 |
| NCT07705438 |
Granzyme B-PET: Predicting Immunotherapy Efficacy in TNBC |
RECRUITING | |
| NCT07679360 |
A Study of Trastuzumab Rezetecan in Combination With Adebrelimab Versus Investigator's Choice of Therapy in Subjects With Residual Triple Negative Breast Cancer |
NOT_YET_RECRUITING | PHASE3 |
| NCT07672431 |
Study of the TheraBionic P1 Device in Patients With Metastatic Triple Negative Breast Cancer After Progression |
NOT_YET_RECRUITING | NA |
| NCT07623369 |
A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors |
RECRUITING | PHASE1 |
| NCT07610525 |
Blood and imagE-guided Optimization of Neoadjuvant Therapy in People With Early Stage Triple-negative Breast cancER - the BETTER Trial |
NOT_YET_RECRUITING | PHASE2 |
| NCT07533123 |
A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care |
RECRUITING | PHASE3 |
| NCT07528768 |
Gemcitabine vs Paclitaxel in Caribbean Women of African Ancestry With Metastatic Triple-Negative Breast Cancer |
NOT_YET_RECRUITING | PHASE2 |
| NCT07503808 |
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types |
RECRUITING | PHASE1 |
